Mithra and Mediner sign LSA for Tibelia® in Hungary

 

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces an exclusive license and supply agreement (LSA) with Mediner for the commercialization of Tibelia® in Hungary.

Tibelia® is a bioequivalent version of Livial® (Merck) developed by Mithra. The product is a synthetic steroid (tibolone) for use in hormone replacement therapy. This includes the relief of postmenopausal symptoms, in addition to prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products. Under the terms of the agreement, Mediner will have the rights to sell the product in Hungary, a market worth approximately EUR 0.6 million2.


Mediner is a Hungarian-based company offering a broad portfolio of in-licensed products to its home market, with a key focus on gynecology. With Tibelia®, the company aims to strengthen its position in Women’s Health.


Next to license fees, Mithra is eligible for annual revenues over the duration of the 10-year contract.


François Fornieri, CEO Mithra Women’s Health: “We are pleased to announce this new agreement for Tibelia®. We expect the product to become an increasingly important source of future revenue, and look forward to additional launches and further partnerships in 2018 and beyond.”

Note

About Mediner

Mediner is a private company headquartered in Hungary. The company was founded in 2000. Next to providing marketing and promotional services to healthcare, Mediner also has a broad portfolio of inlicensed products, with a focus on dermatology, pulmology and gynecology.

 

About Mithra


Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?